100 related articles for article (PubMed ID: 9351907)
21. Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2.
Kinzig-Schippers M; Fuhr U; Zaigler M; Dammeyer J; Rüsing G; Labedzki A; Bulitta J; Sörgel F
Clin Pharmacol Ther; 1999 Mar; 65(3):262-74. PubMed ID: 10096258
[TBL] [Abstract][Full Text] [Related]
22. Modulation of CYP1A2 enzyme activity by indoleamines: inhibition by serotonin and tryptamine.
Agúndez JA; Gallardo L; Martínez C; Gervasini G; Benítez J
Pharmacogenetics; 1998 Jun; 8(3):251-8. PubMed ID: 9682270
[TBL] [Abstract][Full Text] [Related]
23. Human biotransformation of bropirimine. Characterization of the major bropirimine oxidative metabolites formed in vitro.
Wynalda MA; Hauer MJ; Wienkers LC
Drug Metab Dispos; 1998 Oct; 26(10):1048-51. PubMed ID: 9763414
[TBL] [Abstract][Full Text] [Related]
24. Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A.
Niwa T; Shiraga T; Mitani Y; Terakawa M; Tokuma Y; Kagayama A
Drug Metab Dispos; 2000 Sep; 28(9):1128-34. PubMed ID: 10950860
[TBL] [Abstract][Full Text] [Related]
25. Studies on the cytochrome P450 (CYP)-mediated metabolic properties of miocamycin: evaluation of the possibility of a metabolic intermediate complex formation with CYP, and identification of the human CYP isoforms.
Kasahara M; Suzuki H; Komiya I
Drug Metab Dispos; 2000 Apr; 28(4):409-17. PubMed ID: 10725309
[TBL] [Abstract][Full Text] [Related]
26. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
27. Involvement of cytochrome P450 1A in sanguinarine detoxication.
Vrba J; Kosina P; Ulrichová J; Modrianský M
Toxicol Lett; 2004 Jul; 151(2):375-87. PubMed ID: 15183462
[TBL] [Abstract][Full Text] [Related]
28. Rofecoxib is a potent, metabolism-dependent inhibitor of CYP1A2: implications for in vitro prediction of drug interactions.
Karjalainen MJ; Neuvonen PJ; Backman JT
Drug Metab Dispos; 2006 Dec; 34(12):2091-6. PubMed ID: 16985100
[TBL] [Abstract][Full Text] [Related]
29. Development of a whole-cell screening system for evaluation of the human CYP1A2-mediated metabolism.
Chu CC; Pan KL; Yao HT; Hsu JT
Biotechnol Bioeng; 2011 Dec; 108(12):2932-40. PubMed ID: 21755496
[TBL] [Abstract][Full Text] [Related]
30. Contributions of arylacetamide deacetylase and carboxylesterase 2 to flutamide hydrolysis in human liver.
Kobayashi Y; Fukami T; Shimizu M; Nakajima M; Yokoi T
Drug Metab Dispos; 2012 Jun; 40(6):1080-4. PubMed ID: 22446520
[TBL] [Abstract][Full Text] [Related]
31. Effect of dimethyl sulfoxide on in vitro cytochrome P4501A2 mediated phenacetin O-deethylation in human liver microsomes.
Nirogi R; Kandikere V; Bhyrapuneni G; Ponnamaneni RK; Palacharla Rc; Manoharan A
Drug Metab Dispos; 2011 Nov; 39(11):2162-4. PubMed ID: 21825116
[TBL] [Abstract][Full Text] [Related]
32. CYP1A2-mediated biotransformation of cardioactive 2-thienylidene-3,4-methylenedioxybenzoylhydrazine (LASSBio-294) by rat liver microsomes and human recombinant CYP enzymes.
Fraga AG; da Silva LL; Fraga CA; Barreiro EJ
Eur J Med Chem; 2011 Jan; 46(1):349-55. PubMed ID: 21144625
[TBL] [Abstract][Full Text] [Related]
33. Identification of cytochrome P450 1A2 as enzyme involved in the microsomal metabolism of Huperzine A.
Ma X; Wang H; Xin J; Zhang T; Tu Z
Eur J Pharmacol; 2003 Feb; 461(2-3):89-92. PubMed ID: 12586202
[TBL] [Abstract][Full Text] [Related]
34. Comparison of in vitro bioactivation of flutamide and its cyano analogue: evidence for reductive activation by human NADPH:cytochrome P450 reductase.
Wen B; Coe KJ; Rademacher P; Fitch WL; Monshouwer M; Nelson SD
Chem Res Toxicol; 2008 Dec; 21(12):2393-406. PubMed ID: 19548358
[TBL] [Abstract][Full Text] [Related]
35. Potentiation of flutamide-induced hepatotoxicity in mice by Xian-Ling-Gu-Bao through induction of CYP1A2.
Ding Y; Ma H; Xu Y; Yang F; Li Y; Shi F; Lu Y
J Ethnopharmacol; 2021 Oct; 278():114299. PubMed ID: 34090906
[TBL] [Abstract][Full Text] [Related]
36. Production of human metabolites of the anti-cancer drug flutamide via biotransformation in Cunninghamella species.
Amadio J; Murphy CD
Biotechnol Lett; 2011 Feb; 33(2):321-6. PubMed ID: 20931353
[TBL] [Abstract][Full Text] [Related]
37. Dicofol degradation to p,p'-dichlorobenzophenone - a potential antiandrogen.
Thiel A; Guth S; Böhm S; Eisenbrand G
Toxicology; 2011 Apr; 282(3):88-93. PubMed ID: 21291947
[TBL] [Abstract][Full Text] [Related]
38. A Screen of Approved Drugs Identifies the Androgen Receptor Antagonist Flutamide and Its Pharmacologically Active Metabolite 2-Hydroxy-Flutamide as Heterotropic Activators of Cytochrome P450 3A In Vitro and In Vivo.
Blobaum AL; Byers FW; Bridges TM; Locuson CW; Conn PJ; Lindsley CW; Daniels JS
Drug Metab Dispos; 2015 Nov; 43(11):1718-26. PubMed ID: 26265743
[TBL] [Abstract][Full Text] [Related]
39. Caffeine test in predicting flutamide-induced hepatic injury in patients with prostate cancer.
Ozono S; Yamaguchi A; Mochizuki H; Kawakami T; Fujimoto K; Otani T; Yoshida K; Ichinei M; Yamashita T; Hirao Y
Prostate Cancer Prostatic Dis; 2002; 5(2):128-31. PubMed ID: 12497002
[TBL] [Abstract][Full Text] [Related]
40. Measurement of human cytochrome P4501A2 (CYP1A2) activity in vitro.
Polasek TM; Elliot DJ; Miners JO
Curr Protoc Toxicol; 2006; Chapter 4():Unit4.19. PubMed ID: 23045133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
